How Google's Calico aims to fight aging and 'solve death'
The death of death?
- Google's new company Calico will 'tackle aging and illness'
- Many believe that Calico will take a 'big-data' approach to speed the way to health care discoveries
- Exploratory disciplines including cryonics, cloning and nanotechnology hope to extend human life
Plenty of skin care
companies would like us to believe so. And now, the multinational tech
giant Google would like us to think it might be possible too.
Last month Google
announced a new medical company called Calico, whose explicit aim is to
take on aging itself. But what will Google's approach be? And what other
research into prolonging life already exists?
With its proliferation of
businesses, products and services, it would be easy to forget that not
so very long ago Google was just a search engine. Today, offshoots of
the sprawling global corporation can be found researching self-driving cars, developing their own smart phones and tablets and even launching giant balloons into near space.
Amid this growing portfolio of diffuse interests and initiatives has been added their latest company: Calico.
To really make a difference in human health you need to tackle the aging process
João Pedro de Magalhães, biologist
João Pedro de Magalhães, biologist
Calico -- or the
California Life Company -- has been set up to research subjects related
to aging and its associated diseases. Announcing Calico at a media
briefing, Google said that the new and independent company will largely
focus on age-attendant conditions such as Alzheimer's, cancer and heart
disease.
Larry Page,
Google's ever youthful CEO said: "Illness and aging affect all our
families. With some longer term, moonshot thinking around healthcare and
biotechnology, I believe we can improve millions of lives."
But the question is, what
will Calico actually do? At the moment the company isn't giving much
detail away: "(Incoming CEO Arthur Levinson) and I are excited about
tackling aging and illness," Page wrote in his Google+ blog post. But
repeated requests from CNN to interview either Page or Levinson were
politely declined.
In the absence of any real information, many commentators have speculated that Calico will pursue a 'big-data' approach
to health: gathering massive amounts of information from patients and
'crunching it' to help speed the way to health care discoveries. Some
have suggested that Calico's new CEO will take the view that the best
way to tackle aging is to focus on preventing diseases.
Aubrey de Grey
The goal of Calico is to keep people healthy irrespective of their
age, and ill-health is the main cause of death, so increased longevity
will be an inevitable and excellent side-effect of such work.
Aubrey de Grey, Chief Science Officer of SENS Foundation
Aubrey de Grey, Chief Science Officer of SENS Foundation
Aubrey de Grey,
an expert in the field of regenerative medicine, told CNN that it is
too soon to speculate on what Google's approach will be: "in relation to
Calico, I think it's vital to keep in mind that there is essentially no
concrete information about their planned direction and emphasis, and
any guess that they will take a heavily data-driven approach is no more
than a guess."
However, he does think that Calico will not limit its focus to a single disease: "The statements from Page and Levinson
thus far indicate quite strongly that the emphasis will not be just
cancer, or even just a range of specific diseases, but will be 'aging
itself': Page in particular has highlighted the paltry longevity gains
that would arise even from totally eliminating cancer."
João Pedro de Magalhães,
a Portuguese biologist who leads the Integrative Genomics of Aging
group at the University of Liverpool, agrees: "From what I've read, I
don't think the company will mostly focus on cancer. In the Time
interview Larry Page clearly states that solving cancer is 'not as big
an advance as you might think'. This is reminiscent of what experts
studying aging have been saying for a while, which is that to really
make a difference in human health and longevity you need to tackle the
aging process rather than individual age-related diseases."
So where might Calico's
focus lie? A broad range of technologies and therapies that promise life
extension through different means are currently being researched and
tested. CNN Labs takes a look across the scientific landscape to bring you the view from the front line of the war against aging.
Cryonics
Cryonics is a process
where the body -- or occasionally just the head -- is suspended in
liquid nitrogen to 'preserve' it indefinitely. The idea is that in the
future the body will be able to be resuscitated and brought back to
life.
Once the preserve of
celebrities and multimillionaires, cryonics is now gaining traction
among the broader public. Several months ago, The Sunday Times reported
that three senior staff at Oxford University have signed up to have their bodies frozen with two U.S.-based cyonics organizations: the Cryonics Institute and the Alcor Life Extension Foundation.
The head of Russian cryonics firm KrioRus, Danila Medvedev, looks inside a liquid nitrogen filled human storage unit
The cost of cryonics can
vary wildly. The lowest price at the Cryonics Institute is reportedly
$28,000 for 'cryopreservation'; Alcor Life charges customers up to
$200,000 for similar services. But does it work?
The Cryonics Institute underline on their website
that, as yet, their treatments are based on projections of technology
to come rather than present day science: "We firmly believe that with
the incredible advances being made in nanotechnology, medicine and
science today, cryonics has the same potential to become an everyday
reality in the not-so-distant future ... The goal of cryonics is to halt
(the 'dying') process as quickly as possible after legal death, giving
future doctors the best possible chance of reviving the patient by
repairing or replacing damaged tissues, or even entire organs using
advanced computer, nanotech and medical equipment and procedures".
No comments:
Post a Comment